GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Toleranzia AB (OSTO:TOL) » Definitions » Notes Receivable

Toleranzia AB (OSTO:TOL) Notes Receivable : kr0.00 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Toleranzia AB Notes Receivable?

Toleranzia AB's Notes Receivable for the quarter that ended in Mar. 2025 was kr0.00 Mil.


Toleranzia AB Notes Receivable Historical Data

The historical data trend for Toleranzia AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Toleranzia AB Notes Receivable Chart

Toleranzia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Toleranzia AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Toleranzia AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Toleranzia AB Notes Receivable Related Terms

Thank you for viewing the detailed overview of Toleranzia AB's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Toleranzia AB Business Description

Traded in Other Exchanges
N/A
Address
Arvid Wallgrens backe 20, 8th floor, Gothenburg, SWE, 413 46
Toleranzia AB is a Swedish biotechnology company. It develops drugs that harness the power of the immune system to treat autoimmune orphan diseases. The company uses its tolerance technology for drug development, which is based on the identification of disease-specific proteins that are developed into biological drugs, specific to each autoimmune disease. Its drug development pipeline includes TOL2, which is being developed for the treatment of autoimmune orphan disease myasthenia gravis, and TOL3, being developed for another indication in autoimmune orphan diseases, ANCA vasculitis.